Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Expectations dashed.
What do you call realistic? It's closing in on SEVEN years since Bordy announced P2O, and six since the famous "commercialization begins" PR where he said "we're filling tankers right now".
Realistic timeframes are far from the issue here. Blatantly fraudulent statements from the founder, is the issue. P2O doesn't work. Never has. Share price manipulation or not, this company will go bankrupt eventually, since they will never, ever, be able to generate repeatable revenues from processor sales.
Haven't seen those.. you saying they were BUYS?? I always found it pathetic that there was a constant stream of Form 4's of directors selling for "tax obligations" when the amounts where so puny.
Open market buys would indeed be an encouraging sign.
And I'm still down 90% on my position LOL.. I held on all the way down.
Small project, but great exposure IMO. A few more high-profile projects like those will fill our sails with wind...
nee, sorry hoor. twintig = twenty
"de komende twintig maanden"
I'm betting on the latter. In fact, I have a large bet already placed on the latter
IMO the "market" still doesn't even know about this small company. Trading volume has always been crazy thin. When word gets out, this can quickly become a $15 stock.. and 3-5 years from now it could be multiples more than that.
Huge! This is fantastic news! A whole new product line and market, that dwarfs what was already a large and growing market for their power converters.
Hopefully they just license the IP, and let the 800-pound gorilla's integrate the tech into their existing products.
"the global VFD market which is projected to reach $37 billion by 2026"
"The company plans to initially target low voltage AC drives, which make up 71 percent of the addressable market, through licensing and alliance partnerships."
"After undergoing months of testing by independent researchers at the University of Texas Center for Electromechanics (CEM) alongside a popular product from one of the world's leading VFD manufacturers, Ideal Power's PPSA-based VFD yielded superior performance results over the existing technology"
News: RedHill Biopharma Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential of YELIVA™ in Cholangiocarcinoma Cancer
PR below, here is the paper itself: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=7914&path%5B%5D=23169
---
TEL-AVIV, Israel, March 10, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced the publication of an article evaluating the therapeutic potential of YELIVA™ (ABC294640), the Company’s orally-administered first-in-class Sphingosine kinase-2 (SK2) selective inhibitor, in the treatment of cholangiocarcinoma (bile duct cancer). The article, authored by scientists from the Mayo Clinic Cancer Center, the Hollings Cancer Center at the Medical University of South Carolina and Apogee Biotechnology Corporation (“Apogee”), will be published in Oncotarget and is available online on the journal’s website.
The article[1], entitled “Antitumor effect of the novel sphingosine kinase-2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells,” found that SK2 is overexpressed in multiple human cholangiocarcinoma cell lines, including a patient-derived line. The article describes non-clinical studies conducted with YELIVA™ (ABC294640) in these cell lines. The results from these studies demonstrated that YELIVA™ inhibited cancer proliferation and induced apoptosis in these cholangiocarcinoma cancer cells. Furthermore, YELIVA™ inhibited STAT3 phosphorylation, one of the key signaling pathways regulating cell proliferation and survival, and also induced autophagy. In addition, YELIVA™ in combination with sorafenib, an FDA-approved multikinase inhibitor for the treatment of hepatocellular carcinoma and renal cell carcinoma (NEXAVAR® marketed by Bayer AG), synergistically inhibited the proliferation of cholangiocarcinoma cells.
The authors concluded that these findings provide preliminary insight into the possible use of YELIVA™ as an anticancer drug for cholangiocarcinoma treatment, as well as novel evidence that SK2 may be a rational therapeutic target in the treatment of this cancer. Additionally, a combination of YELIVA™ with sorafenib and/or autophagy inhibitors may provide novel strategies for the treatment of cholangiocarcinoma.
Reza Fathi, RedHill’s Senior VP R&D, said: “We are pleased to announce the publication of this important article in a well-respected, peer-reviewed journal. The findings described in this publication provide further insight into the mechanism of the anticancer activities of YELIVA™, a novel Sphingosine kinase-2 (SK2) inhibitor, and suggest that YELIVA™ could potentially be effective in treating cholangiocarcinoma cancer. Notably, it was found that YELIVA™ inhibited STAT3 phosphorylation, one of the key signaling pathways regulating cholangiocarcinoma cell proliferation and survival. We continue to diligently advance the clinical research of YELIVA™ for multiple indications. We have initiated a Phase I/II study with YELIVA™ in patients with refractory/relapsed diffuse large B-cell lymphoma and plan to initiate two additional Phase II studies, for multiple myeloma and radioprotection, during 2016. We are planning additional clinical programs with this novel and promising drug candidate for oncology, inflammatory and gastrointestinal indications.”
Charles D. Smith, Ph.D., Apogee’s President and CEO and a co-author of the article, added: “We are pleased that these results provide a rationale for use of YELIVA™ in a very difficult to treat malignancy. These results further add to the breadth and importance of YELIVA™’s mechanism of action studies in multiple human tumors.”
Cholangiocarcinoma is a rare cancer that develops in the bile ducts, characterized by its late diagnosis and high mortality rates. Cholangiocarcinoma is the second most common primary liver tumor, accounting for approximately 10-15% of all hepatobiliary malignancies[2]. Although a rare cancer, the incidence and mortality rates of cholangiocarcinoma have been increasing worldwide in the last three decades. The five year survival rates following diagnosis have not increased during this time period, and remain at 10%[3]. Surgery is the only curative treatment option, but only for the minority of patients diagnosed with early-stage disease.
RedHill announced in October 2015 positive top-line results from a Phase I study with YELIVA™ in patients with advanced solid tumors, the majority of which were gastrointestinal cancer patients, including pancreatic, colorectal and cholangiocarcinoma cancers. Top-line results demonstrated that YELIVA™ can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic activity, based on levels required in preclinical models. The study included the first-ever longitudinal analysis of plasma S1P levels as a potential pharmacodynamic (PD) biomarker for activity of a sphingolipid-targeted drug. The administration of YELIVA™ resulted in a rapid and pronounced decrease in S1P levels over the first 12 hours, with return to baseline at 24 hours, which is consistent with clearance of the drug, with several patients having prolonged stabilization of disease.
A Phase I/II clinical study was initiated in the U.S. evaluating YELIVA™ in patients with refractory/relapsed diffuse large B-cell lymphoma (DLBCL), including in patients with HIV-related DLBCL. The study is being conducted at the Louisiana State University Health Sciences Center (LSUHSC) in New Orleans and is supported by a grant awarded to Apogee from the NCI Small Business Technology Transfer (STTR) program, as well as additional support from RedHill. The Phase I/II clinical study in patients with refractory/relapsed diffuse large B-cell lymphoma and the Phase I clinical study in cancer patients with advanced solid tumors are registered on www.ClinicalTrials.gov, a web-based service by the U.S. National Institute of Health which provides public access to information on publicly and privately supported clinical studies.
A Phase I/II study with YELIVA™ for the treatment of refractory or relapsed multiple myeloma is planned to be initiated in the second quarter of 2016. The study will be conducted at Duke University Medical Center. The study is supported by a $2 million grant from the NCI Small Business Innovation Research Program (SBIR) awarded to Apogee in conjunction with Duke University, with additional support from RedHill.
A Phase II clinical study to evaluate YELIVA™ as a radioprotectant to prevent mucositis in cancer patients undergoing therapeutic radiotherapy is planned to be initiated in the U.S. during the second half of 2016, subject to regulatory and other conditions.
Disappointing numbers, but huge potential for 2016 and beyond, especially the Korean project worth $100MM alone!
Japan also looking to kick off Gas-to-Power projects on a very large scale.. I hope Hydrogenics can get a chunk of that!
Amazing project, and such a beautiful looking building.
I also found this article about it, containing some additional information (emphasis added):
http://www.thenational.ae/business/energy/dubai-firm-to-create-one-of-worlds-largest-solar-glass-facades-at-danish-school
A Dubai company has won an order to supply a solar glass facade to a school in Denmark in what is one of the largest projects of its kind in the world.
Now it wants to wants to introduce the same technology in buildings across the UAE.
Emirates Insolaire, a unit of Dubai Investments, will supply about 12,000 coloured solar glass panels to the Copenhagen International School.
Once fitted, the panels will create one of the largest photovoltaic (PV) facades of its kind, the company said.
The facade will supply more than half of the school’s annual electricity consumption, producing about 300 megawatt hours per year.
The panels are part of the building’s photovoltaic system, which allows solar panels to be integrated directly into building structures such as windows.
“The project is very important for Emirates Insolaire and offers the company significant inroads into Europe and the rest of the world for its unique technology," said Rafic Hanbali, a managing partner of Emirates Insolaire. “Emirates Insolaire has brought in a paradigm shift in solar applications by introducing aesthetic appeal to facades coupled with added efficiency."
Construction has started and is expected to be completed by the end of June.
It also plans to install its Kromatix technology on two buildings in Dubai Investments Park.
Mr Hanbali said the company was targeting a little more than 1 MW by the end of the year. “But what I expect is to have about 15,000 to 20,000 square metres of our technology installed on 10 to 15 buildings over the next 20 months in Dubai, and about 50,000 to 70,000 sq metres worldwide."
He said the technology could meet from 10 to 50 per cent of a building’s energy requirements. In Dubai, each square metre will produce above 200 kWh annually.
Stephane Le Gentil, the chief executive of Etihad Esco, a Dubai Electricity and Water Authority joint venture service company, said the priority should be to reduce energy consumption. “We look at how to make savings, and then we’ll look at what we can do for alternative power," he said.
Worth highlighting some bits of this news:
one of the largest photovoltaic buildings-of-its-kind in the world with photovoltaic modules
the first school across the globe to have complete photovoltaic façade and one of the largest building integrated photovoltaic [BIPV] projects in the world
will supply more than half of the school’s annual electricity consumption
one of the largest building-integrated solar power plants in Denmark
the project has begun and is expected to be completed by end of June 2016
First tranche of the $15MM direct investment in to EVM is complete by Valentia (funds in the bank). $100MM direct project financing to come. Hugely encouraging for the prospects of someday seeing an updraft tower! Where will the first one be? Arizona, Texas, India?? Looking forward to concrete project news, hopefully soon!
News: Emirates Insolaire’s Solar Glass At Danish School To Create One Of World’s Largest Photovoltaic Facades
Emirates Insolaire LLC, a pioneer in the development and application of the unique KromatixTM solar technology and a joint venture of Dubai Investments & SwissINSO Holding Inc., has announced that it has won the supply contract of over 12,000 coloured solar glass for Copenhagen International School [CIS] Nordhavn in Copenhagen, Denmark, to create one of the largest photovoltaic buildings-of-its-kind in the world with photovoltaic modules.
A total of 12,000 solar panels, covering a total area above 6,000 square meters, will be installed on the façade of CIS Nordhavn, making it the first school across the globe to have complete photovoltaic façade and one of the largest building integrated photovoltaic [BIPV] projects in the world. Construction of the project has begun and is expected to be completed by end of June 2016.
SolarLab is producing the photovoltaic modules with Emirates Insolaire’s KromatixTM solar glass while C.F. Moller Architects, one of Scandinavia's oldest and largest architectural companies, are the project architects.
Once completed, the panels, which will be individually angled to create a sequin-like effect, will supply more than half of the school’s annual electricity consumption – producing about 300 MWh per year, which is equivalent to energy needs of 70 single-family homes – and will be one of the largest building-integrated solar power plants in Denmark, thus setting new benchmarks in sustainability in the country.
The KromatixTM solar glass for the project are ready to ship, and Emirates Insolaire, along with its partners, organized a special reception at Dubai Investments House, Dubai Investments Park to mark the milestone. The reception was attended by H.E. Morten Siem Lynge, Consul General of Denmark in Dubai, Khalid Bin Kalban, Managing Director and CEO of Dubai Investments, as also senior representatives from Emirates Insolaire, SolarLab and CIS.
Khalid Bin Kalban said: “The project in Copenhagen, being executed by Dubai Investments-Emirates Insolaire with KromatixTM technology, falls within the scope of the Memorandum of Understanding signed between the governments of UAE and Denmark to boost cooperation in the fields of renewable energy and sustainability. Dubai Investments is committed to sustainable business practices in line with the initiatives undertaken by the UAE government to diversify energy sources. Through Emirates Insolaire, Dubai Investments is thrilled to offer its world-class technology to prestigious projects across the globe.”
Rafic Hanbali, Managing Partner of Emirates Insolaire, said: “Emirates Insolaire is privileged to receive the contract for the Copenhagen International School Nordhavn. The project is very important for Emirates Insolaire and offers the company significant inroads into Europe and the rest of the world for its unique technology. Emirates Insolaire has brought in a paradigm shift in solar applications by introducing aesthetic appeal to façades coupled with added efficiency.”
John Bo Jacobsen, Chairman of the Board of the Property Foundation Copenhagen International School, said: “We are proud that with the construction of the new school we can integrate innovative architecture into our teaching principles. The goal of the school is to enhance students’ competences in an international environment so that they become responsible citizens of the world with a focus on sustainability.”
Peter Roedder, Managing Director of SolarLab, added: “SolarLab is privileged to have won this iconic project for Copenhagen International School; and is a major milestone in our journey. Our partnership with Emirates Insolaire will go a long way in introducing this unique coloured solar panel technology for our projects.”
Emirates Insolaire, which installed the world’s first KromatixTM coloured solar PV modules in Switzerland and Austria last year, is witnessing considerable interest for its solar panels globally, amidst rising demand and awareness towards a more sustainable future. The company is expecting an exponential demand with projects and products rapidly entering all markets.
One of the important advantages of the Emirates Insolaire technology, apart the beauty of its products, is that the coloured KromatixTM solar panels offer high efficiency while allowing vertical integration and less demand on horizontal required space.
src: http://www.dubaicityguide.com/site/news/news-details.asp?newsid=58432
NEWS: Resonant Signs MOU with New Customer to Design Three Duplexers
GOLETA, Calif.-- Resonant Inc. (NASDAQ: RESN), a developer of innovative filter designs for radio frequency front-ends (RFFEs) for the mobile device industry, today announced it has entered into a memorandum of understanding (MOU) with a new customer to develop surface acoustic wave (SAW) duplexer designs for three separate bands.
The MOU includes an upfront payment to Resonant and additional payments upon completion of the designs. This brings the number of filters Resonant is developing under MOUs to five. Additionally, Resonant has ongoing development projects for multiplexers, as well as a reconfigurable, or tunable, filter design.
CEO and Co-Founder Terry Lingren stated: “This MOU with a new customer comes less than a month after our recently announced MOU with an existing customer. The three duplexer designs for our customer accelerate the timing of potential design wins and increase the likelihood of our designs ultimately being incorporated into phones. Our customers are beginning to understand the capabilities of our team and design tools. These capabilities broaden our customers’ design capacities and give them cost-effective, competitive products in much less time than is normal in the industry.
“The proliferation of bands and the more demanding specifications for those bands are dramatically increasing the number of filter designs required for smartphones. Additionally, design capacity is rapidly becoming the bottleneck in the RF front-end industry. Both of these trends play to our strength in designing complex filters quickly and efficiently, enabling our customers to meet their increasingly aggressive market timelines and respond to the market opportunities presented by the OEMs,” concluded Lingren.
(take from: http://ir.resonant.com/press-releases/detail/205 )
Huge, IMO. Lends major credibility to the company. This is outstanding news. Congratulations to Leo and the whole company for moving the science forward to the point where talent like Dr. Sonis is attracted. Very exciting.
2 years ago, they'd said that John himself! needed to man the P2O operations and that nobody else was qualified. Maybe they'll need to hire him back. Hope they pay him well.
A page right out of the John Bordynuik playbook. Unbelievable.
P2O is supposed to be PROFITABLE. Hence re-starting #3 should GENERATE revenue for the company. The fact that it will require a fresh round of fund-raising (and dilution) is a pretty obvious sign of its viability.
Great news (albeit expected) with the final Phase III results out today.
Blockbuster around the corner, it would appear.
Anyone know how long we can expect a Phase III "confirmatory" study to take? Could they get the product on the market during 2017?
Modest open market buy from the CEO just showed up in SC filing. Sends a positive signal, but it was only $20k worth. Doesn't counter the damage (mostly perception) caused by the CTO's sales though.
Still like this company a lot. Nothing has changed except the share price, and that's more of a reason to buy IMO, than sell.
Excellent review of this company's prospects, thanks for posting that!
The company is right to pound their fists .. this is one of the better bio-tech stocks available now, IMO, even with the recent drop in the sector overall.
And this one: "SolarWindow is initially targeting the five million tall towers and commercial buildings in the United States, which consume almost 40% of the electrical energy generated"
5 million 50+ floor buildings in the USA? Wow. And THESE buildings use 40% of all electricity?
Uh huh, yeah.
It's hard to take a company seriously when they make statements like this: "producing 50-times greater energy than rooftop solar when modeled for a 50-story building". Clearly this has more to do with the relative surface area of the facades to the roof of a skyscraper. Duh.
No numbers to back anything up, so far. 1 year pay-back? Show us some numbers. What are the assumptions? (probably solar irradiation of Dubai with 365 cloudless days and no obstructing buildings, nor dirty windows.. ie.. these are lab numbers, not real-world projections).
I love the idea, but their supposed break-out announcement last year was a dud IMO. Hype and more hype with no proof.
What on earth is an "actual P2O investor"?? Surely you're not referring to the numbskulls like myself who used to invest in JBII but still think it can be a commercially viable business? Surely such people don't exist anymore.. not in 2016. No way.
To answer my own question, I realize it's a completely different approach, and that phage therapy more closely resembles anti-biotic therapy.
I pulled this from the website of a company that specialized in it, which gives a good explanation:
"While bacteria may develop resistance to phages, it is incomparably easier to develop new phages than new antibiotics. In nature, as bacteria evolve resistance, relevant phages will evolve in concert. While this adaptability is most often played out in nature, it may also be harnessed in the laboratory. A few weeks are needed to obtain new phages for a newly-emerging strain of resistant bacteria. This is in favorable, sharp contrast to the seven to twelve years required to discover and develop a new antibiotic and get it approved by the FDA in the US. In other words, when a highly resistant bacteria subspecies (known in the press as a "superbug’) appears, a "superphage" may be readily isolated and produced against it."
Trying to stay on-topic here.. I was just curious to learn more about the larger space of the post-antibiotic era: and solutions to it in general (e.g. natural killers, phages, defensis mimics, etc.)
I watched an interesting TV report on Phage Therapy as an approach to treat infections in the face of mounting resistance issues with antibiotics. This approach has been sidelined for decades since antibiotics came on the scene, but is now attracting interest in the R&D (and regulatory) space in Europe. It's only legal only in a few countries today, however, with Georgia being chief among them.
I was wondering if anyone here has heard of it, and can speak to its differences with defensin mimetics.
A future application of QD's: http://phys.org/news/2016-02-quantum-dot-solids-silicon-wafer.html
I'll take part of my post back: if there were any (positive) authoritative assessment of a scientific nature on the company's drugs or trials, then they absolutely should re-circulate those.
I agree. I expect the lawsuit will indeed be dismissed, but likely to the disappointment of CTIX shareholders: neither a surge in PPS, nor any repercussions for Mako or Rosen.
The CEO's FB post and shareholder update referencing the SA article was weak. It almost seemed like CTIX saw that article as some kind of vindication, but it's just another article by a nobody (that matters, that is).
Vindication will come when the suit is dismissed.
The company needn't spend anytime re-circulating third-party assessments of ANYTHING related to their business: neither legal, nor scientific, nor administrative.
My advice for Leo: stop paying attention to the punters on message boards, and keep your head down: advance the science, and keep the company running. Many great strides lately to be proud of. Yesterday's SA article (while I agreed with it) is nothing to be proud of or officially endorsed, IMO.
Can anyone comment how this new "passive wifi" may affect RESN's IP advantage?
http://www.wired.co.uk/news/archive/2016-02/24/passive-wifi-breakthrough
Is it significant that on the ClinicalTrials page for Kevetrin the "Plan to Share Data" is now "Yes" (previously "Not Recorded")? Does this imply at all that the findings will be peer-reviewed?
Now that the trial is over, I'd love to see the findings analyzed and commented by other reputable sources. IMO it may generate the interest in CTIX, that is clearly still lacking.
If this MOU is legit, could be a huge turnaround in the share price for this company. I've been following for about a year now, took only a small position, but with news of an MOU (though of course there is nothing binding in there) I may take a bigger position. PPS is near all-time lows, and the company has some compelling IP.
I think you mean law-abiding and morally intact management was lacking.
I think I realize now why P2O operations were only efficient when John Bordynuik was driving the forklift (remember THAT claim by the company two years ago!?). It's because while the rest of the workers weren't looking, he'd head off into the corner of the warehouse where all the virgin HDPE plastic was sitting, and load THAT stuff into the hopper! You know, the stuff that was worth $600/ton when recycled? Not the dirty, mixed-plastic, co-mingled stuff they claimed would rain diesel and then auto-cleanout.
They don't make me nervous in the slightest way, as they were scheduled in the past. I'm pretty sure he's as upset that he chose to sell while the PPS is so low, although yes.. he can stop the selling if he wanted, but he has plenty plenty more.
Daily volume traded of this company has almost never exceeded 1% of the float, so it's really super thin. When the inflection point is upon us (in terms of cash burn becoming cash flow), and when the company attracts more investors.. it will turn quickly IMO.
By 2018 the company should be largely profitable on their 30 and 125kW units alone. BTRAN and VFD application may also just be getting started then too, which can only add to the potential.
This is one of those investments where I don't get nervous at all when the share price slides 50%.. I just scratch my head and wonder what the heck people are thinking, and then wish I were able to buy more at such attractive prices.
"As previously reported, the Company Plastic2Oil, Inc. (the “Company”) entered into four related agreements with EcoNavigation, LLC (“EcoNavigation”) in connection with the supply of plastic-to-oil, or P2O, processors by the Company to EcoNavigation. As of January 27, 2016, such agreements expired and were not renewed by the parties, however, the parties continue to pursue joint opportunities for the sale of processors to third parties.."
filed 10 minutes ago:
http://www.sec.gov/Archives/edgar/data/1381105/000149315216007488/form8-k.htm
R.I.P. JBI
I liked this part: "I am particularly excited to be joining at its near-term planned transition into a commercial stage specialty Pharma company."
I think RedHill is a terrific investment at these levels -- modest risk and excellent upside potential for the patient investor.
On the call yesterday, Brdar mentioned that their tests with VFD at the UofTexas were still on-going, and that they're using this work to determine how best to get into the VFD market with a product offering. More information expected around the end of March.
To put that sector into context, checkout slide 15 on the company's latest presentation from December, showing the expected market size for power converters by 2020, per sector:
http://content.equisolve.net/_fb278700058dbe0db1917887608b59df/idealpower/db/109/1997/pdf/IdealPower-Presentation-December2015.pdf
VFDs is $34bn, versus battery & microgrid at $2bn.
Clearly if the work they're doing at UofTexas bears fruit and they develop a competitive product for the VFD space, it's an absolute game changer for this already promising young company.
VFD background info from an article posted back in 2010 about the UofTexas research and testing being done with Ideal's PPSA
http://ati.utexas.edu/ati-member-company-ideal-power-converters-unveils-low-harmonic-vfd-motor-drive-in-field-tests-with-austin-energy-and-city-of-austin/